Table 1.
Prevalence of diabetes according to severity among COVID-19 infected patients.
| Author | Date | Area | DM Prevalence | DM Prevalence |
DM Prevalence |
Mortality |
|||
|---|---|---|---|---|---|---|---|---|---|
| DM/total COVID-19 patients | Non-severe cases | Severe cases | Survivors | Non-survivors | nonDM | DM | |||
| Chen N[24] | 2020.1.1–2020.1.20 | Wuhan, China | 12/99 (12%) |
||||||
| Liu K[25] | 2019.12.30–2020.1.24 | Wuhan, China |
14/137 (10.2%) |
||||||
| Song F[26] | 2020.1.20–2020.1.27 | Shanghai, China | 3/51 (6%) |
||||||
| Yang W[27] | 2020.1.17–2020.2–10 | Wenzhou, China | 9/149 (6%) |
||||||
| Chen Q[28] | 2020.1.1.-2020.3.11 | Zhejiang China |
14/145 (9.7%) |
7/102 (6.9%) |
7/43 (16.3%) |
||||
| Huang C[29] | 2019.12.16–2020.1.2 | Wuhan, China |
8/41 (20%) |
No ICU 7/28 (25%) |
ICU 1/13 (8%) |
||||
| Liu W[30] | (2020.1.15) | Wuhan China |
5/78 (6.4%) |
3/67 (4.5%) |
2/11 (18.2%) |
||||
| Wang D[31] | 2020.1.1–2020.1.28 | Wuhan China |
14/138 (10.1%) |
6/102 (5.9%) |
8/36 (22.2%) |
||||
| Xu X[32] | 2020.1.10–2020.1.26 | Hangzhou,China | 1/62 (2%) |
0/29 (0%) |
1/33 (3%) |
||||
| Zhang JJ[33] | 2020.1.16∼ 2020.2.3 |
Wuhan, china | 17/140 (12.1%) |
9/82 (11%) |
8/58 (13.8%) | ||||
| Guan WJ[34] | 2020.1.29 | 31 provinces, China | 81/1099 (7.4%) | 53/926 (5.7%) | 28/173 (16.2%) | 63/1032 (6.1%) | 18/67 (26.9%) | ||
| Wu C[35] | 2019.12.25–2020.1.26 | Wuhan China |
22/201 (10.9%) |
6/117 (5.1%) | 16/84 (19%) | 5/40 (12.5%) | 11/44 (25%) | ||
| Deng Y[36] | 2020.1.1–2020.1.21 | Wuhan, China | 26/225 (11.5%) |
9/116 (7.8%) | 17/109 (15.6%) | ||||
| Yang X[37] | 2019.12–2020.1.26 | Wuhan, china | 9/52 (17%) |
2/20 (10%) | 7/32 (22%) | ||||
| Zhou F[38] | 2019.12.29–2020.1.31 | Wuhan, china | 36/191 (19%) | 19/137 (14%) |
17/54 (31%) | ||||
| Wu Z[39] | CDC china | 1102/44672 (5.3%) |
133/15536 (0.9%) |
80/1102 (7.3%) |
|||||
| Guo W[40] | 2020.02.10.-2020.02.29 | Wuhan, China | 37/174 (21.2%) | 5/137 (3.6%) | 4/37 (10.8%) |
||||
| Yan Y[41] | 2020.1.10–2020.2.24 | Wuhan, China | 48/193 (24.9%) |
69/145 (47.6%) |
39/48 (81.3%) | ||||
| Zhu L[42] | 2019.12.30–2020.03.20 | Hubei, China |
952/7337 (13.0%) | 172/6385 (2.7%) |
74/952 (7.8%) |
||||
| KNCCMC[43] | 2020.1.19–2020.2.17 | Korea | 2/28 (7.1%) |
||||||
| KSI& Korea CDC[44] | 2020.03.10 | Korea | 16/54 (29.6%) |
||||||
| Korea CDC[45] | 2020.03.12 | Korea | 23/66 (36.5%) |
||||||
| Korea [46] |
2020. | Korea | 29/110 (26.4%) |
1/81 (1.2%) | 5/29 (17.2%) |
||||
| Gentile S[5] | 2020.03.27 | Italia | 86,433 (33.9%) |
||||||
| Richardson[6] | 2020.3.1–2020.4.4 | New York USA | 1808/5700 (33.8%) |
||||||
| USA CDC[45], [47] | 2020.2.12–2020.3.28 | USA | 784/7162 (10.9%) | Not hospital 331/5143 (6%) Non-ICU 251/1037 (24%) |
ICU 148/457 (32%) |
||||
CDC, Centers for Disease Control and Prevention; KNCCMC, Korea National Committee for Clinical Management of COVID-19.